top of page
LYNPARZA Maintenance Therapy: The Only PARPi FDA-approved in First-line Maintenance for Women with BRCAm*
Mon, Jul 29
|Davio's Northern Italian Steakhouse
LYNPARZA is now the ONLY PARPi FDA-approved in first-line maintenance for women with sBRCA*- and gBRCA-mutated† advanced ovarian cancer, following response to platinum-based chemotherapy.
Registration is Closed
See other events
Time & Location
Jul 29, 2019, 6:00 PM
Davio's Northern Italian Steakhouse, 75 Arlington St, Boston, MA 02116, USA
Guests
About The Event
LYNPARZA Maintenance Therapy: The Only PARPi FDA-approved in First-line Maintenance for Women with BRCAm* Advanced Ovarian Cancer in Complete or Partial Response to Platinum-based Chemotherapy
Presented by
THOMAS KRIVAK, MD
RSVP is required by 07/26/2019.
To register or for more information, contact
Katie Naylor at katie.naylor@astrazeneca.com or (203) 980-2353
bottom of page